Abstract
Abstract
Introduction
Hepatitis E virus (HEV) is one of the leading causes of acute viral hepatitis. There are thought to be 20 million infections per year in poorer nations with inadequate sanitation. In Egypt, awareness about the possible hazards linked to HEV infection is limited due to low socioeconomic and educational levels. Only a small number of sequences have been characterized, making HEV study in Egypt constrained. Numerous factors may have contributed to this neglect. Various extra-hepatic symptoms of HEV infection include neurological problems are recognized. Many European nations have implemented regular HEV monitoring, or targeted screening of blood provided by patients at greater risk to stop the spread of HEV by transfusion.
Aim
Assess the prevalence of HEV infection in asymptomatic blood donors. Increasing awareness about HEV testing in patients with some unexplained neurological disorders.
Methods
Cross-sectional study involving 550 patients: 500 apparently healthy blood donors and 50 patients with some neurological disorders. All subjects were tested for serological markers (IgG and IgM) for HEV using ELISA technique in addition to HEV RNA PCR testing for seropositive patients.
Results
Five hundred asymptomatic blood donors (370 males and 130 females), ages ranging from 20 to 50 years (median 33), 22.6% of them tested positive for HEV (IgG and IgM) of which 2 subjects only had positive HEV RNA PCR testing. In the second group 50 patients (26 males and 24 females) with various unexplained neurological disorders. Liver functions were within normal or showed only a mild increase. Forty-four percent of the patients had positive serology for HEV, with 6 patients testing positive for HEV RNA on PCR.
Conclusion
No need for mass screening for HEV serology among blood donors. HEV infection needs to be considered in patients with unexplained neurological disorders even if the liver functions are not markedly elevated.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. World Health Organisation (WHO) (2022).Hepatitis E.WHO, Geneva: Switzerlandl; https://www.who.int/news-room/fact-sheets/detail/hepatitis-e. Accessed 4 June 2022.
2. Li P, Liu J, Li Y, Su J, Ma Z, Bramer WM et al (2020) The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis. Liver Int 40(7):1516–1528
3. El-Mokhtar MA, Othman ER, Khashbah MY, Ismael A, Ghaliony MA, Seddik MI, Sayed IM (2020) Evidence of the extrahepatic replication of hepatitis E virus in human endometrial stromal cells. Pathogens 9(4):295
4. Sayed IM, Seddik MI, Gaber MA, Saber SH, Mandour SA, El-Mokhtar MA (2020) Replication of hepatitis E virus (HEV) in primary human-derived monocytes and macrophages in vitro. Vaccines (Basel) 8(2):239
5. El-Mokhtar MA, Seddik MI, Osman A, Adel S, Abdel Aziz EM, Mandour SA, Mohammed N, Zarzour MA, Abdel-Wahid L et al (2020) Hepatitis E virus mediates renal injury via the interaction between the immune cells and renal epithelium. Vaccines (Basel) 8(3):454